Microfabrication techniques such as 3D printing, have enabled the synthesis of highly specialised and controlled microchips with well-defined chemical and physical environments. The integration of such chips with modern cell culture techniques has created a new way to mimic the in vivo. Growing excitement around these microphysiological models of human organs on microfluidic cell culture chips has led to a marked interest and investment in such technologies, yet many challenges remain ahead, not least of all scalability and adaptation for high throughput screening. Join us for Cambridge Healthtech Institute’s Inaugural Organ-on-a-Chip and MicroPhysiological Systems symposium, where this promising preclinical model will be explored and evaluated, where future steps towards more accurate and reliable preclinical trials will be taken.

Single cell omics are rapidly redefining how scientists view heterogeneous cell populations in oncology. With high-throughput single cell technologies being developed for imaging, mass spectrometry and sequencing applications, the impact on healthcare industries is growing momentum, though this potential requires much nurturing before single cell technologies can be integrated for use with biomarkers for diagnostics and therapeutics. At Cambridge Healthtech Institute’s Inaugural Single-Cell Analysis symposium, receive updates on the latest single cell technologies to disrupt the market and compare and contrast their benefits to existing technologies.

Artificial Intelligence (AI) and Machine Learning (ML) are more than just buzz words being used in the pharmaceutical and biotechnology industry. There is now a steady stream of publications and evidence outlining what these terms really mean, how they can be applied in a drug discovery and development setting, and how much value they add in terms of saving time, effort and costs. Cambridge Healthtech Institute’s Inaugural AI & Machine Learning for Drug Discovery symposium will bring together computational and bioinformatics experts along with discovery scientists to discuss how some of these technologies and platforms are being used and how well they are living up to their promise. It will include a diverse set of talks that will highlight how AI and ML can be used for target identification, drug design and optimization, predicting drug toxicity and adverse events. This unique one-day symposium will help attendees meet and interact with experts and peers from around the world to share ideas and gain some understanding about the opportunities and limitations in using these emerging informatics tools and platforms.